Drug Interactions of Mobocertinib (Exkivity): Essential Guide for Lung Cancer Patients

Tags: Mobocertinib Exkivity Lung cancer targeted therapy Drug interactions EGFR mutation

1. What is Mobocertinib?

Mobocertinib (brand name Exkivity) is a targeted therapy for NSCLC with EGFR Exon 20 insertion mutations. As a third-generation EGFR inhibitor, it effectively controls tumor growth.

2. Key Interaction Mechanisms

Primarily metabolized by CYP3A4, co-administration with drugs affecting this enzyme may cause:

• Increased drug levels (CYP3A4 inhibitors)

• Reduced efficacy (CYP3A4 inducers)

• Elevated cardiac toxicity risk (QT-prolonging drugs)

3. High-Risk Drug Combinations

Absolute Contraindications

• Strong CYP3A4 inhibitors:

• Antifungals (ketoconazole)

• Macrolide antibiotics

• HIV protease inhibitors

• Strong CYP3A4 inducers:

• Antiepileptics

• Rifampin

• St. John's wort

4. Clinical Management

• Maintain updated medication records

• Regular ECG and LFT monitoring

• Dose adjustment requirements:

• 50% dose reduction with strong inhibitors

5. Patient Q&A

Q1: Safe pain relief options?

A: Acetaminophen preferred; avoid NSAIDs if platelet counts are low.

Q2: Managing diarrhea?

A: Use loperamide promptly and maintain hydration. Report persistent cases (>48hrs).

Q3: Vaccination recommendations?

A: Avoid live vaccines. Prioritize COVID-19/influenza vaccines during treatment.

For authentic medication access: Dingxiang International provides direct India-sourced medications, trusted by patients nationwide. Consult Dingxiang International客服 for reliable procurement channels.